The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has issued a Medical Device Alert (MDA) providing updated advice to assist the early detection of soft tissue reactions in patients implanted with metal-on-metal (MoM) hip replacements.
MHRA, in consultation with its independent Metal-on-Metal Expert Advisory Group (MoM EAG), has continued to monitor the performance of MoM hip joint articulations for the occurrence of soft tissue reaction associated with these devices. The majority of patients with MoM hip replacements currently have well-functioning hips. However, some patients will develop progressive soft tissue reactions to the wear debris associated with MoM articulations. Data from the 13th Annual Report of the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man, published in 2016, continued to show a risk of adverse soft tissue reaction to particulate debris. MHRA's clinical orthopaedic experts have also observed that soft tissue necrosis may occur in both asymptomatic and symptomatic patients, and believe early detection of these events should give a better revision outcome should this becomes necessary. This MDA is being sent to general practitioners (GPs) for information only, in case patients ask about the contents of this notice. GPs need take no further action on receipt of this alert.
MHRA is instructing users to take the following actions:-
* In all cases, the benefit of ionising radiation screening should be weighed against the risks from radiation exposure on an individual patient basis, in line with the requirements of The Ionising Radiation (Medical Exposure) Regulations 2000.
For details, please refer to the MHRA's website:
https://www.gov.uk/drug-device-alerts/all-metal-on-metal-mom-hip-replacements-updated-advice-for-follow-up-of-patients
Posted on 30 June 2017